Literature DB >> 16018857

Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis.

Anthony Aizer1, Eric H Stern, J Anthony Gomes, Alvin S Teirstein, Robert E Eckart, Davendra Mehta.   

Abstract

The utility of programmed ventricular stimulation to predict future arrhythmic events in patients with cardiac sarcoidosis is unknown. Similarly, the long-term benefit of implantable cardioverter-defibrillators (ICDs) in cardiac sarcoidosis has not been established. Thirty-two consecutive patients with cardiac sarcoidosis underwent programmed ventricular stimulation. Patients with spontaneous or inducible sustained ventricular arrhythmias (n = 12) underwent ICD insertion. All study patients were followed for the combined arrhythmic event end point of appropriate ICD therapies or sudden death. Mean length of follow-up to sustained ventricular arrhythmia or sudden death was 32 +/- 30 months. Five of 6 patients (83%) with spontaneous sustained ventricular arrhythmias and 4 of 6 patients (67%) without spontaneous but with inducible sustained ventricular arrhythmias received appropriate ICD therapy. Two of 20 patients (10%) with neither spontaneous nor inducible sustained ventricular arrhythmias experienced sustained ventricular arrhythmias or sudden death. Programmed ventricular stimulation predicted subsequent arrhythmic events in the entire population (relative hazard 4.47, 95% confidence interval [CI] 1.30 to 15.39) and in patients who presented without spontaneous sustained ventricular arrhythmias (relative hazard 6.97, 95% CI 1.27 to 38.27). No patient with an ICD died of a primary arrhythmic event. In patients with spontaneous or inducible sustained ventricular arrhythmias, mean survival from first appropriate ICD therapy to death or cardiac transplant was 60 +/- 46 months, with only 2 patients dying or reaching transplant at study end. In conclusion, programmed ventricular stimulation identifies patients with cardiac sarcoidosis at high risk for future arrhythmic events. ICDs effectively terminate life-threatening arrhythmias in high-risk patients, with significant survival after first appropriate therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16018857     DOI: 10.1016/j.amjcard.2005.03.059

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

Review 1.  Cardiac Sarcoidosis.

Authors:  Pranav Mankad; Brian Mitchell; David Birnie; Jordana Kron
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  A 34-year-old man with cardiac arrhythmias and lymphadenopathy.

Authors:  Nico Abegunewardene; Tommaso Gori; Markus Vosseler; Kai-Helge Schmidt; Christian Taube; Felix Post; Christoph Düber; Karl-Friedrich Kreitner; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2010-03-09       Impact factor: 5.460

3.  Risk stratification in cardiac sarcoidosis: The tricky business of predicting the future.

Authors:  Jordana Kron
Journal:  J Cardiovasc Electrophysiol       Date:  2019-07-23

Review 4.  Cardiac sarcoidosis.

Authors:  Matthew M Zipse; William H Sauer
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

5.  A Diagnostic and Therapeutic Approach to Arrhythmias in Cardiac Sarcoidosis.

Authors:  Brian A Houston; Carolyn Park; Monica Mukherjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

Review 6.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

7.  Ventricular tachycardia as the first manifestation of cardiac sarcoidosis.

Authors:  Felix Mehrhof; Martin Stockburger; Hartwig Schuette; Wilhelm Haverkamp; Rainer Dietz
Journal:  BMJ Case Rep       Date:  2009-04-28

Review 8.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

Review 9.  Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.

Authors:  Joseph P Lynch; Jennifer Hwang; Jason Bradfield; Michael Fishbein; Kalyanam Shivkumar; Roderick Tung
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

Review 10.  Idiopathic giant cell myocarditis and cardiac sarcoidosis.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.